SillaJen logo — company profile

SillaJen

Founded 2003 United States San Francisco, United States 28 employees Venture round Total: $12.00M Biotechnology, Health Care

General Information

Company Name SillaJen
Founded Year 2003
Location United States San Francisco, United States
Employees 28
Industries Biotechnology, Health Care
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with SillaJen. To contact SillaJen, visit sillajen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About SillaJen

SillaJen Biotherapeutics, Inc. is a biotechnology company headquartered in San Francisco, founded in 2003. The company focuses on the research, development, and manufacturing of oncolytic viruses to treat cancer. It operates in one of the largest biotech clusters in the world and handles Clinical Operations, Regulatory Affairs, Research and Development, Manufacturing, Alliance Management, and Accounting for clinical trials. SillaJen has a South Korean base with satellite offices in Seoul and San Francisco, CA. Their primary focus is on developing and commercializing oncolytic immunotherapy products using the SOLVETM platform, with its lead product Pexa-Vec currently in Phase 3 trials for the treatment of advanced primary liver cancer. This promising endeavor has attracted a significant $12.00M Venture Round investment from Medivate Partners on 21 March 2016. For more information, visit www.sillajen.com.

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $12.00M 1
Medivate Partners
21 Mar 2016

SillaJen Alternatives & Competitors

View All Alternatives
SillaJen vs
Genelux
Genelux United States

Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improvi...

Post-IPO Equity
34 employees
Biopharma, Biotechnology
SillaJen vs

Boston Biomedical, Inc. is a leading developer of novel cancer therapeutics with the goal of signifi...

Venture round
31 employees
Biotechnology, Health Care
SillaJen vs
Flaskworks
Flaskworks United States

Developing closed system cell culture devices for clinical manufacturing of cellular therapies.

Grant
5 employees
Biotechnology, Health Care

FAQ About SillaJen

SillaJen Biotherapeutics, Inc. is located in San Francisco, one of the largest and most innovative biotech clusters in the world. Sillajen Biotherapeutics focuses on the research, development and manufacturing of oncolytic viruses to treat cancer; we are responsible for Clinical Operations, Regulato...
SillaJen was founded in 2003.
SillaJen is headquartered in San Francisco, United States.
SillaJen operates in Biotechnology and Health Care.
SillaJen has approximately 28 employees.
SillaJen has completed 1 funding round, raising a total of $12.00M. The latest funding stage is Venture round.
Top alternatives and competitors to SillaJen include Genelux, Boston Biomedical, Inc., Flaskworks, CytoVac AB, Pharmacyclics, an AbbVie Company. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
SillaJen and Genelux are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for SillaJen, https://bouncewatch.com/company/sillajen, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes